McKenna's Drug Handbook for Nursing & Midwifery, 7e

Diagnostic preparations     1299

Contraindications Contraindicated in individuals with known hypersensitivity to the preparation. care considerations • Increased risk of nephrogenic systemic fibrosis in individuals with acute or chronic renal failure or acute renal insufficiency, or during the perioperative period in liver transplantation. Renal function should be assessed in all individuals prior to the procedure. • For individuals on chronic haemodialysis, initiate haemodialysis promptly following administration of gadobutrol to increase elimination. • Closelymonitor individualfordevelopment of anaphylactic reaction. Ensure emergency management equipment is available and in correct working order. • Monitor vital signs closely following procedure. • If there is a need to repeat administration, there should be at least 7 hours between doses. Patient teaching • Advise person to report any adverse effects.

gadobutrol Gadovist

Pregnancy risk category B3 Use in sport: Permitted Available forms Solution for injection: 604.72 mg/mL (1.0 mmol/mL) in 7.5 mL, 15 mL Indications & dosages ➤ EnhancementofMRI— Adultsandchildrenover2years: 0.1mmol/ kg bodyweight (0.1 mL/kg bodyweight) by IV bolus. Action Diagnosticradiopharmaceuticalpreparation that assists detection of altered perfusion in areas of the cerebrum. Route Onset Peak Duration IV Immediate Unknown 6 hrs Adverse reactions CNS: convulsions, dizziness, dysgeusia, headache, loss of consciousness , tremor. CV: cardiac arrest , circulatory failure , hypertension, hypotension, pallor, palpi­ tations, tachycardia. Eye: conjunctivitis, oedema of eyelids. GI: dry mouth, nausea, vomiting. GU: acute kidney injury . Respiratory: bronchospasm , cough, cyanosis, dyspnoea, laryngeal oedema, oropharyngeal oedema , pulmonary oedema , sneezing. Musculoskeletal: nephrogenic systemic fibrosis . Skin: erythema, facial oedema, flushing, rash, pruritus, urticaria. Other: anaphylactic reaction , hyper­ sensitivity, injection site reaction, malaise. Interactions None reported.

gadodiamide Omniscan Pregnancy risk category B3 Use in sport: Permitted Available forms

Solutionfor injection: 287mg/mL (0.5mmol/ mL) in 5 mL, 10 mL, 15 mL, 20 mL in vials, ampoules and prefilled syringes Indications & dosages ➤ EnhancementofCNSorwhole-bodyMRI— Adultsandchildrenover2years: 0.1mmol/ kg bodyweight (0.2 mL/kg bodyweight) by IV bolusor infusionupto100kgbodyweight. Above 100 kg bodyweight, 20 mL is usually sufficient.